Beleodaq FDA Approval History
FDA Approved: Yes (First approved July 3, 2014)
Brand name: Beleodaq
Generic name: belinostat
Dosage form: Injection
Company: Spectrum Pharmaceuticals, Inc.
Treatment for: Peripheral T-cell Lymphoma
Beleodaq (belinostat) is a histone deacetylase (HDAC) inhibitor for the treatment of peripheral T-cell lymphoma (PTCL).
Development Timeline for Beleodaq
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.